Biocon
Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Headquarters at Electronic City, Bangalore | |
| Company type | Public |
|---|---|
Traded as | BSE: 532523 NSE: BIOCON |
| ISIN | INE376G01013 |
| Industry | Biopharmaceutical |
| Founded | 1978 |
| Founder | Kiran Mazumdar-Shaw |
| Headquarters | , India |
Key people | Kiran Mazumdar-Shaw (Executive Chairperson) Peter Bains (CEO & Managing Director, Biocon Limited) Shreehas P Tambe (CEO & Managing Director, Biocon Biologics Limited) |
| Products | Biologics Small molecules Branded formulations Research services |
| Revenue | ₹11,550 crore (US$1.4 billion) (FY2023) |
| ₹2,888 crore (US$360 million) (FY2023) | |
Net income | ₹787 crore (US$99 million) (FY2023) |
| Total assets | ₹52,044 crore (US$6.5 billion) (2023) |
| Total equity | ₹22,489 crore (US$2.8 billion) (2023) |
Number of employees | 16,545 (Mar 2023) |
| Subsidiaries | Biocon Biologics Syngene International |
| Website | www |
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb (Itolizumab) and KRABEVA (Bevacizumab).
Syngene International Limited (Syngene) is a publicly listed subsidiary of Biocon, operating in the contract research and development organization.